Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe
This article was originally published in The Pink Sheet Daily
The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.
You may also be interested in...
Teva CEO Jeremy Levin provided additional glimpses of the company’s new strategy on a Q3 earnings call in advance of an investor meeting on Dec. 11, where he and Teva management will reveal their full agenda. Levin again put the emphasis on “focus” and “discipline” over “pure growth,” confirmed the company’s ‘confidence in the MS drug laquinimod, and highlighted several senior management appointments that reflect Teva’s new priorities.
Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.
Europe's tough pricing and reimbursement environment may make it a graveyard for growth in innovative drugs, but there's still plenty of upside in generics, particularly of the branded, specialist kind.